+1 - Roche

More documents

Recommendations

Info

<strong>Roche</strong> First quarter 2003 Charles Sabbah Head of Pharma Strategic Marketing Exane Pharma Seminar Paris May 12 th , 2003 r 2
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as “believes”, “expects”, “anticipates”, “projects”, “intends”, “should”, “seeks”, “estimates”, “future” or similar expressions or by discussion of strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity or news coverage. 3
Page 4 and 5: Sales first quarter 2003 A good sta
Page 6 and 7: Highlights first quarter 2003 Strat
Page 8 and 9: 2003 and 2002 First quarter 2003 av
Page 10 and 11: Diagnostics Division r 10
Page 12 and 13: Roche Diagnostics continues to outp
Page 14 and 15: Molecular Diagnostics Strategic dea
Page 16 and 17: Near Patient Testing Demand increas
Page 18 and 19: Applied Science Entry into new mark
Page 20 and 21: Diagnostics sales by business area
Page 22 and 23: Performance Strategic initiatives a
Page 24 and 25: Cancer is a disease of the genome D
Page 26 and 27: Diagnostics Outlook • Continued d
Page 28 and 29: Pharmaceuticals sales (adjusted) Q1
Page 30 and 31: Sales of first quarter 2003 (vs. Q1
Page 32 and 33: Local sales growth Q1 '03 vs. Q1 '0
Page 34 and 35: First quarter Prescription* sales K
Page 36 and 37: MabThera - continued success First
Page 38 and 39: Xeloda The powerful, yet gentle che
Page 40 and 41: Pegasys and Copegus Rapid and signi
Page 42 and 43: Copegus new & total prescription sh
Page 44 and 45: CellCept A cornerstone of transplan
Page 46 and 47: Rocephin Influenced by external fac
Page 48 and 49: Our main primary care products Dila
Page 50 and 51: Roche R&D pipeline today Total of 6
Page 52 and 53:
Our growth objectives for 2003 and
show all

+1 - Roche

Create successful ePaper yourself

Delete template?

Save as template?